Cantor Fitzgerald Weighs in on Rockwell Medical, Inc.’s FY2022 Earnings (NASDAQ:RMTI)

Rockwell Medical, Inc. (NASDAQ:RMTIGet Rating) – Research analysts at Cantor Fitzgerald raised their FY2022 earnings per share estimates for Rockwell Medical in a research report issued to clients and investors on Wednesday, May 18th. Cantor Fitzgerald analyst B. Folkes now expects that the company will earn ($3.48) per share for the year, up from their prior forecast of ($3.85).

Rockwell Medical (NASDAQ:RMTIGet Rating) last released its quarterly earnings results on Thursday, May 19th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.99) by $0.15. The firm had revenue of $16.12 million for the quarter, compared to analyst estimates of $18.80 million. Rockwell Medical had a negative net margin of 51.27% and a negative return on equity of 474.88%. During the same quarter in the previous year, the company earned ($0.08) EPS.

RMTI has been the subject of several other research reports. Zacks Investment Research upgraded shares of Rockwell Medical from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a research note on Friday. StockNews.com started coverage on shares of Rockwell Medical in a report on Saturday. They set a “hold” rating for the company.

NASDAQ RMTI opened at $1.67 on Monday. The company has a debt-to-equity ratio of 5.21, a quick ratio of 1.49 and a current ratio of 1.27. Rockwell Medical has a 1 year low of $1.62 and a 1 year high of $11.66. The company has a fifty day moving average of $4.23 and a two-hundred day moving average of $4.39.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Marshall Wace LLP acquired a new stake in shares of Rockwell Medical in the first quarter valued at approximately $57,000. Metropolitan Life Insurance Co NY acquired a new stake in shares of Rockwell Medical in the first quarter valued at approximately $106,000. Renaissance Technologies LLC grew its position in shares of Rockwell Medical by 81.1% in the fourth quarter. Renaissance Technologies LLC now owns 225,534 shares of the company’s stock valued at $92,000 after purchasing an additional 101,000 shares during the last quarter. Verdence Capital Advisors LLC grew its position in shares of Rockwell Medical by 25.1% in the fourth quarter. Verdence Capital Advisors LLC now owns 443,545 shares of the company’s stock valued at $182,000 after purchasing an additional 88,980 shares during the last quarter. Finally, Perkins Capital Management Inc. boosted its position in Rockwell Medical by 34.5% during the fourth quarter. Perkins Capital Management Inc. now owns 2,957,025 shares of the company’s stock worth $1,212,000 after acquiring an additional 758,400 shares during the last quarter. Institutional investors own 27.88% of the company’s stock.

Rockwell Medical Company Profile (Get Rating)

Rockwell Medical, Inc operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores.

Featured Stories

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.